Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels.
Peter Suenaert, Anneleen Segers, Leen Rymenans et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the effects of pasteurized Akkermansia muciniphila MucT on insulin sensitivity and GLP-1 production in 142 adults with metabolic syndrome. After 4 months, there was no significant difference in whole-body insulin sensitivity compared to placebo. However, prediabetic participants showed a 12% improvement in hepatic insulin sensitivity and increased GLP-1 levels after 3 months of treatment.
Key findings
- No significant difference in whole-body insulin sensitivity after 4 months of treatment.
- 12% improvement in HOMA-based hepatic insulin sensitivity in prediabetic participants (p = 0.05).
- Increased post-OGTT GLP-1 excursion compared to placebo (p < 0.01).
- Participants with low baseline Akkermansia levels experienced significant health improvements.
Why it matters
Understanding the impact of gut microbiota on metabolic health is crucial for developing targeted interventions. This study highlights the potential of Akkermansia muciniphila in improving insulin sensitivity and GLP-1 production, particularly in individuals with low baseline levels.